Search
AbbVie Inc
ABBVAdd to Watchlist
201.550USD
-1.350-0.67%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
356.49BMarket Cap
98.93P/E TTM
More Details of AbbVie Inc Company
AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.
AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.
The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'
AbbVie Inc Info
Ticker SymbolABBV
Company nameAbbVie Inc
IPO dateJan 02, 2013
CEOMichael (Robert A)
Number of employees55000
Security typeOrdinary Share
Fiscal year-endJan 02
Address1 N Waukegan Rd
CityNORTH CHICAGO
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code60064
Phone18479327900
Websitehttps://www.abbvie.com/
Ticker SymbolABBV
IPO dateJan 02, 2013
CEOMichael (Robert A)
Company Executives of AbbVie Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
44.85K
+4.23%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
--
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
28.96K
--
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
16.50K
--
Mr. Timothy J. Richmond
Mr. Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
6.13K
-346.66%
Mr. Thomas J. (Tom) Falk
Mr. Thomas J. (Tom) Falk
Independent Director
Independent Director
4.20K
+42.76%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
204.37K
+0.05%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
134.63K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
55.37K
+5.41%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
44.85K
+4.23%
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
38.46K
--
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
35.65K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
17.56B
28.71%
Immunology-RINVOQ
8.30B
13.58%
Immunology-HUMIRA
4.54B
7.42%
Neuroscience-Botox Therapeutic
3.77B
6.16%
Neuroscience-Vraylar
3.62B
5.92%
Other
23.36B
38.20%
By RegionUSD
Name
Revenue
Proportion
United States
44.49B
72.75%
International
13.04B
21.32%
All other countries
2.63B
4.30%
Germany
1.74B
2.84%
Japan
1.27B
2.08%
Other
-2.01B
-3.29%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Immunology-SKYRIZI
17.56B
28.71%
Immunology-RINVOQ
8.30B
13.58%
Immunology-HUMIRA
4.54B
7.42%
Neuroscience-Botox Therapeutic
3.77B
6.16%
Neuroscience-Vraylar
3.62B
5.92%
Other
23.36B
38.20%
Shareholding Stats
Updated: 5 hours ago
Updated: 5 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vanguard Capital Management, LLC
6.50%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Vanguard Portfolio Management, LLC
2.80%
Geode Capital Management, L.L.C.
2.52%
Other
78.23%
Shareholders
Shareholders
Proportion
Vanguard Capital Management, LLC
6.50%
BlackRock Institutional Trust Company, N.A.
5.38%
State Street Investment Management (US)
4.58%
Vanguard Portfolio Management, LLC
2.80%
Geode Capital Management, L.L.C.
2.52%
Other
78.23%
Shareholder Types
Shareholders
Proportion
Investment Advisor
54.81%
Investment Advisor/Hedge Fund
21.61%
Research Firm
3.14%
Bank and Trust
2.37%
Pension Fund
2.27%
Sovereign Wealth Fund
1.54%
Insurance Company
0.67%
Hedge Fund
0.45%
Family Office
0.22%
Other
12.91%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
5703
1.36B
77.09%
+26.64M
2025Q4
5311
1.33B
74.86%
+1.37M
2025Q3
5386
1.32B
74.95%
+8.86M
2025Q2
5326
1.32B
74.78%
+2.41M
2025Q1
5334
1.32B
74.15%
+3.84M
2024Q4
5267
1.31B
73.92%
+9.35M
2024Q3
4970
1.30B
74.13%
-1.24M
2024Q2
4907
1.30B
73.33%
+14.47M
2024Q1
4916
1.28B
72.48%
+1.37M
2023Q4
4861
1.27B
72.12%
+10.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
95.07M
5.38%
+2.29M
+2.47%
Dec 31, 2025
State Street Investment Management (US)
80.94M
4.58%
+1.12M
+1.40%
Dec 31, 2025
Geode Capital Management, L.L.C.
44.63M
2.52%
+4.19M
+10.36%
Dec 31, 2025
JP Morgan Asset Management
34.79M
1.97%
-1.63M
-4.49%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
25.67M
1.45%
+2.57M
+11.11%
Dec 31, 2025
Capital Research Global Investors
25.41M
1.44%
+177.37K
+0.70%
Dec 31, 2025
Charles Schwab Investment Management, Inc.
25.17M
1.42%
-788.26K
-3.04%
Dec 31, 2025
Fidelity Management & Research Company LLC
21.48M
1.21%
+1.53M
+7.67%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Pharmaceutical ETF
9.64%
First Trust NASDAQ Pharmaceuticals ETF
8.05%
Health Care Select Sector SPDR Fund
7.89%
Proshares Ultra Health Care
7.62%
iShares U.S. Healthcare ETF
7.57%
JPMorgan Healthcare Leaders ETF
6.87%
Simplify Health Care ETF
6.73%
Fidelity MSCI Health Care Index ETF
6.5%
Harbor Health Care ETF
6.18%
iShares Core High Dividend ETF
5.9%
View more
VanEck Pharmaceutical ETF
Proportion9.64%
First Trust NASDAQ Pharmaceuticals ETF
Proportion8.05%
Health Care Select Sector SPDR Fund
Proportion7.89%
Proshares Ultra Health Care
Proportion7.62%
iShares U.S. Healthcare ETF
Proportion7.57%
JPMorgan Healthcare Leaders ETF
Proportion6.87%
Simplify Health Care ETF
Proportion6.73%
Fidelity MSCI Health Care Index ETF
Proportion6.5%
Harbor Health Care ETF
Proportion6.18%
iShares Core High Dividend ETF
Proportion5.9%
Dividend
A total of
40.87B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 19, 2026
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on May 15, 2026 going ex on Apr 15, 2026 with reinvestment option
Apr 15, 2026
May 15, 2026
Apr 15, 2026
Oct 31, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option
Jan 16, 2026
Feb 17, 2026
Jan 16, 2026
Sep 05, 2025
ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 14, 2025
Oct 15, 2025
Jun 20, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 13, 2025
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
View more
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
